OncoMethylome is a molecular diagnostics company developing gene methylation tests for early detection of cancer and for personalized treatment decisions.
OncoMethylome boasts a broad product development pipeline consisting of ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, Schering-Plough Corp., GlaxoSmithKline Biologicals, Abbott, Millipore Corporation's BioScience Division, and EXACT Sciences Corp. OncoMethylome’s products are based on methylation technology invented by Johns Hopkins University (USA).

Established in January 2003, OncoMethylome has offices in Belgium, the USA, and in The Netherlands.

Speaker profile

Lucija Turcinov, MBA, Director, Corporate Strategy & Investor Relations

Ms. Lucija Turcinov is responsible for corporate development, investor relations, shareholder matters and public relations at OncoMethyome. Prior to joining OncoMethylome Sciences, Ms. Turcinov was a Principal at the strategic advisory company The Parthenon Group (Boston, MA, USA), where she advised senior management of private and public companies on corporate strategy. Mrs. Turcinov holds an MBA from the Wharton School, and a BSE from Princeton University